TTRX
What one share of Turn Therapeutics holds
Pharmaceutical Preparations
Our business is dependent on successful clinical trials of our products as well as FDA clearances/approvals of our products. We have three FDA clearances for medical devices, two of which were obtained by the fourth quarter of 2017.
Turn Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.29 |
|---|---|
| Cash and investments | $0.33 |
| Debt | $0.20 |
| Book value | $0.02 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.07 | — | −$0.05 | — | −$0.01 |
| 2025 | — | −$0.12 | — | −$0.09 | — | $0.16 |